课题基金 / 基金详情

Predicting response to non-PAP therapies in OSA using PSG-derived endotypes

Predicting response to non-PAP therapies in OSA using PSG-derived endotypes
使用 PSG 衍生的内型预测 OSA 对非 PAP 疗法的反应
批准号:
10440108
负责人:
DAVID ANDREW WELLMAN
金额:
$81.62万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-09-15 至 2026-07-31

项目摘要

项目成果

DAVID ANDREW WELLMAN的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 阻塞性睡眠呼吸暂停(OSA)是一种常见的疾病,通常会导致严重的健康后果 由于除持续气道正压治疗(CPAP)外几乎没有其他治疗选择,因此仍未得到充分治疗。 可供选择的治疗方法包括下颌前移装置(MADS)和舌下神经 刺激(HGNS)。然而,这些治疗并不总是有效的,成功的预测因素是 很难理解或者很难获得。此外,这些治疗失败的患者往往得不到治疗。 因此容易受到阻塞性睡眠呼吸暂停综合征的临床后果的影响。 在前一次资助期间,我们开发了评估慢性阻塞性肺疾病病理生理内型的方法。 OSA(咽部塌陷、环路增益、咽部肌肉补偿和觉醒阈值)以及 临床多导睡眠图显示呼吸道塌陷的主要部位(腭部、舌部、侧壁、会厌部) (PSG)。这笔赠款的目标是应用这些方法来1)寻找MAD和HGNS反应的预测因子 2)在MAD和HGNS无反应者中测试内型特异性药物治疗。我们的假设是 根据PSG确定的这些内型/塌陷部位是MAD和HGNS的重要预测因子 回应。我们还假设,添加一种针对异常内型的药物,例如高环 Gain,可用于更有效地治疗MAD和HGNS无应答者。 在前两个目标中,生理内型和崩溃的部位将从 使用在前一个赠款周期中开发的方法的临床PSG。然后,患者将经历MAD(目标1) 或HGNS(AIM 2)治疗。将进行后续的PSG检查以评估治疗的成功。vbl.使用 多变量Logistic回归,将确定成功的重要生理预测因素。 在目标3中,在以前的目标中未能通过MAD或HGNS的患者,大约三分之一 个人,将使用针对最异常内型的药物(用于高环增益的乙酰唑胺, 托莫西汀联合奥昔布宁治疗咽肌代偿不良,曲唑酮治疗低觉醒 阈值)。最近的证据表明,这些药物可以操纵内型。药物将会是 同时给予MAD或HGNS治疗(联合治疗)。 目标1和目标2有望找到MAD和HGNS反应的重要生理预测因子, 分别使用从临床PSG导出的新度量。目标3预计将提供原则证明 对于治疗MAD和HGNS衰竭的药物方法,原本有限制的患者 治疗方案。最终,这些研究有可能改善非CPAP患者的选择 替代方案,拓宽阻塞性睡眠呼吸暂停综合征的治疗选择。
英文摘要
ABSTRACT Obstructive Sleep Apnea (OSA) is a common disorder with serious health consequences that often remains undertreated due to few therapeutic options beyond continuous positive airway pressure (CPAP). Alternative treatments are available, such as mandibular advancement devices (MADs) and hypoglossal nerve stimulation (HGNS). However, these treatments are not always effective, and the predictors of success are poorly understood or difficult to obtain. Furthermore, patients who fail these therapies are often left untreated and therefore susceptible to the clinical consequences of OSA. In the previous grant period, we developed methods for estimating the pathophysiological endotypes of OSA (pharyngeal collapsibility, loop gain, pharyngeal muscle compensation, and arousal threshold), as well as the primary site of airway collapse (palate, tongue, lateral walls, epiglottis), from the clinical polysomnogram (PSG). The objective of this grant is to apply these methods to 1) find predictors of MAD and HGNS response and 2) test endotype-specific pharmacotherapies in MAD and HGNS non-responders. Our hypothesis is that these endotypes/sites of collapse, as determined from the PSG, are important predictors of MAD and HGNS response. We also hypothesize that the addition of a drug targeting an abnormal endotype, e.g., high loop gain, can be used to more effectively treat MAD and HGNS non-responders. In the first two aims, the physiological endotypes and sites of collapse will be determined from the clinical PSG using the methods developed in the previous grant cycle. Patients will then undergo MAD (Aim 1) or HGNS (Aim 2) therapy. A follow-up PSG will be performed to evaluate the success of treatment. Using multivariable logistic regression, the significant physiological predictors of success will be determined. In Aim 3, the patients who fail MAD or HGNS in the previous aims, approximately one-third of individuals, will be treated with a drug targeting the most abnormal endotype (acetazolamide for high loop gain, atomoxetine-plus-oxybutynin for poor pharyngeal muscle compensation, or trazodone for low arousal threshold). Recent evidence suggests that these drugs can manipulate the endotypes. The drug will be administered concurrently with MAD or HGNS treatment (combination therapy). Aims 1 and 2 are expected to find the important physiological predictors of MAD and HGNS response, respectively, using novel metrics derived from the clinical PSG. Aim 3 is expected to provide proof-of-principle for a pharmacologic approach to treating MAD and HGNS failures, patients who otherwise have limited treatment options. Ultimately, these studies have the potential to improve patient selection for non-CPAP alternatives and broaden the treatment options for OSA.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Predicting response to non-PAP therapies in OSA using PSG-derived endotypes
  • 批准号:
    10705062
  • 项目类别:
  • 资助金额:
    $79.65万
  • 财政年份:
    2022
  • 负责人:
    DAVID ANDREW WELLMAN
  • 依托单位:
Project 5
Project 5
Project 5
海外基金